BioForce Nanosciences sees control shift, executive departures
On April 15, 2026, Merle Ferguson, a director and majority shareholder, sold 26,700,000 shares representing 79.65% of outstanding common stock to Nexus Capital Investments, Inc. for $400,000, transferring control of the company. On June 17, 2026, co-CEOs Steven Gagnon and John LaViolette and Vice-President Sasha Shapiro resigned, and the board appointed Richard Kaiser as interim CEO and Scott Mager as director. The company is transitioning from vitamin supplements to oil and gas operations.
Key facts
- Merle Ferguson sold 26,700,000 shares (79.65% of outstanding stock) to Nexus Capital Investments, Inc. on April 15, 2026
- Nexus Capital paid $400,000 from corporate funds; no loans involved
- Steven Gagnon and John LaViolette resigned as Co-CEOs on June 17, 2026
- Sasha Shapiro resigned as Vice-President on June 17, 2026
- Richard Kaiser appointed interim Chief Executive Officer on June 17, 2026
- Scott Mager appointed as Director effective June 15, 2026
- Company transitioning from vitamin supplement industry to oil and gas industry
Why it matters
The filing documents a change-of-control event where a new investor (Nexus Capital) acquired majority ownership at a substantial discount, followed immediately by the departure of both sitting CEOs and the VP, positioning a long-serving CFO/director as interim CEO—indicating a complete management turnover aligned with a strategic pivot to oil and gas operations.
Developing story
- NT 10-Q
- NT 10-K
- 8-Kthis filing
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-18. Not investment advice. View the source filing on SEC.gov →